Klivira
Request demo

Streamlining Medicare Xarelto Prior Authorization for Rivaroxaban

Efficiently manage **Medicare Xarelto prior authorization** processes with Klivira's specialized automation, designed to navigate the distinct requirements of Original Medicare and Part D plans.

For revenue cycle directors and prior authorization coordinators, managing DOAC approvals like rivaroxaban (Xarelto) under Medicare presents unique challenges. Understanding the nuances between Original Medicare and Medicare Advantage, alongside Part D formulary requirements, is critical for timely patient access and claims processing. Klivira provides a robust solution to streamline these complex workflows.

Understanding Xarelto (Rivaroxaban) in the Medicare Context

Xarelto (rivaroxaban) is a direct oral anticoagulant (DOAC) indicated for critical conditions such as atrial fibrillation and venous thromboembolism (VTE). For Medicare beneficiaries, its formulary tier, any associated step therapy requirements, and quantity limits are determined by individual Medicare Part D plans, which operate under CMS-approved guidelines to ensure appropriate utilization.

Navigating Medicare Xarelto Prior Authorization Requirements

Prior authorization for Xarelto under Medicare depends significantly on the specific coverage. Original Medicare (Parts A and B) has limited PA requirements, with most drug coverage, including Xarelto, falling under Medicare Part D. Medicare Advantage (MA) plans, which often bundle Part D benefits, may implement more extensive PA protocols that align with their specific formularies and utilization management strategies.

Klivira's Approach to Medicare Xarelto PA Automation

Klivira streamlines the prior authorization process for Xarelto by adapting to the diverse Medicare landscape. For Part D plans, our system integrates with PBM and payer portals, applying plan-specific formulary, step therapy, and quantity limit logic. For any medical benefit PA related to Xarelto administration under Original Medicare, Klivira routes submissions through the appropriate Medicare Administrative Contractor (MAC), such as Noridian, NGS, WPS, Palmetto, FCSO, or Novitas, based on jurisdiction.

Key Considerations for Xarelto Prior Authorization Under Medicare

  • Verify the patient's specific Medicare coverage type (Original Medicare, Medicare Advantage, Part D).
  • Consult the patient's Part D plan formulary for Xarelto's specific tier, step therapy, and quantity limits.
  • Review National Coverage Determinations (NCDs) and Local Coverage Determinations (LCDs) for medical necessity criteria, especially for related medical services.
  • Be aware of MAC-specific submission channels for limited medical benefit prior authorizations under Original Medicare.
  • Note that CMS-0057-F primarily impacts Medicare Advantage plans and has limited applicability to Traditional Medicare for PA turnaround times.

Optimizing Workflows and Reducing Denials

Manual Xarelto prior authorizations under Medicare are prone to delays and denials due to varying Part D plan rules and MAC-specific routing complexities. Klivira's platform automates data extraction from EMRs, applies intelligent policy logic based on NCDs, LCDs, and Part D formularies, and submits requests via the correct digital channels. This approach significantly reduces administrative burden, improves data accuracy, and accelerates approval times, ensuring timely patient access to critical DOAC therapy.

Frequently asked questions

Does Original Medicare require prior authorization for Xarelto?

Original Medicare (Parts A and B) generally has limited prior authorization requirements. Xarelto is typically covered under Medicare Part D, which is administered by private plans. These Part D plans establish their own formularies and may require prior authorization or step therapy for Xarelto based on their specific coverage criteria.

How do Medicare Part D plans handle Xarelto prior authorization?

Medicare Part D plans, operated by commercial insurers, manage pharmacy prior authorizations for drugs like Xarelto. They adhere to CMS-approved formularies, which may include specific tiers, step therapy protocols, or quantity limits for rivaroxaban. Klivira integrates with these Part D plan systems to streamline submissions and ensure compliance with their requirements.

What are common reasons for Xarelto prior authorization denials under Medicare?

Common denial reasons for Xarelto prior authorizations under Medicare Part D often include failure to meet step therapy requirements, lack of documented medical necessity as per plan criteria, or incomplete submission of required clinical information. Klivira helps mitigate these issues by ensuring complete and accurate submissions, aligning with payer policies.

How does Klivira handle the different Medicare contractors for Xarelto PA?

For the limited instances where Xarelto-related medical services might require prior authorization under Original Medicare, Klivira's platform is designed for MAC-aware routing. It identifies the responsible Medicare Administrative Contractor (e.g., Noridian, NGS, WPS) based on jurisdiction and facilitates submission through their specific channels, ensuring correct and timely processing.

Are National Coverage Determinations (NCDs) and Local Coverage Determinations (LCDs) relevant for Xarelto PA?

NCDs and LCDs provide medical necessity criteria for services covered under Medicare Part A and B. While Xarelto itself is a Part D drug, these policies can be relevant for associated medical services or diagnostics related to its use. Klivira incorporates NCD and LCD logic to ensure compliance with medical necessity guidelines where applicable, enhancing approval rates.

Related coverage

Other xarelto prior authorization by payer

Other xarelto prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo